{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:39:22Z","timestamp":1793882362244,"version":"4.7.0"},"reference-count":263,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for over 90% of all cases. Patients with advanced-stage HCC are referred to systemic treatment. Although some advances in HCC therapy have been made in recent years, the prognosis for patients remains poor due to drug resistance, tumor relapse, and metastasis, implying that overall survival remains a challenge. Many studies have shown that tumor-initiating stem cells, also known as cancer stem cells (CSCs), play essential roles in tumorigenesis, metastasis, and treatment resistance in HCC and that future cancer treatments could be significantly improved by targeting this cell population subset. Different markers of CSCs from HCC have been identified, and intracellular signaling pathways and extracellular factors have been reported as targets capable of removing this cell subpopulation, highlighting the possibility of developing targeted drugs to eradicate HCC CSCs. In this review, we highlight emerging small compounds that target HCC CSCs to provide new insights and guide future research. Drugs in the preclinical and clinical trial development stages were selected and discussed.<\/jats:p>","DOI":"10.1038\/s41419-025-07983-5","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:36:14Z","timestamp":1756730174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Sara P.","family":"Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa M.","family":"Bomfim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-2063","authenticated-orcid":false,"given":"Daniel P.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"7983_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"7983_CR2","unstructured":"American Cancer Society. Cancer Facts & Figures 2025. Atlanta: American Cancer Society; 2025."},{"key":"7983_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2509-x","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang G, Wang Q, Liang N, Xue H, Yang T, Chen X, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020;11:313. https:\/\/doi.org\/10.1038\/s41419-020-2509-x.","journal-title":"Cell Death Dis"},{"key":"7983_CR4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683\u201391. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3055.","journal-title":"JAMA Oncol"},{"key":"7983_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333. https:\/\/doi.org\/10.1002\/hep.29466.","journal-title":"Hepatology"},{"key":"7983_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet"},{"key":"7983_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamasurg.2022.7989","volume":"158","author":"ZJ Brown","year":"2023","unstructured":"Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410\u201320. https:\/\/doi.org\/10.1001\/jamasurg.2022.7989.","journal-title":"JAMA Surg"},{"key":"7983_CR8","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","volume":"149","author":"J Zucman-Rossi","year":"2015","unstructured":"Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226\u20131239.e4. https:\/\/doi.org\/10.1053\/j.gastro.2015.05.061.","journal-title":"Gastroenterology"},{"key":"7983_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.gendis.2023.02.050","volume":"11","author":"A Gajos-Michniewicz","year":"2023","unstructured":"Gajos-Michniewicz A, Czyz M. WNT\/\u03b2-catenin signaling in hepatocellular carcinoma: the aberrant activation, pathogenic roles, and therapeutic opportunities. Genes Dis. 2023;11:727\u201346. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.050.","journal-title":"Genes Dis"},{"key":"7983_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1367364","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Cui T, Wei F, Zhou Z, Sun Y, Gao C, et al. Wnt\/\u03b2-Catenin signaling pathway in hepatocellular carcinoma: pathogenic role and therapeutic target. Front Oncol. 2024;14:1367364. https:\/\/doi.org\/10.3389\/fonc.2024.1367364.","journal-title":"Front Oncol"},{"key":"7983_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4251\/wjgo.v13.i4.197","volume":"13","author":"MC Guan","year":"2021","unstructured":"Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: from bench to bedside. World J Gastrointest Oncol. 2021;13:197\u2013215. https:\/\/doi.org\/10.4251\/wjgo.v13.i4.197.","journal-title":"World J Gastrointest Oncol"},{"key":"7983_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604. https:\/\/doi.org\/10.1038\/s41575-019-0186-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7983_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","volume":"32","author":"A Vogel","year":"2021","unstructured":"Vogel A, Martinelli E. ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014.","journal-title":"Ann Oncol"},{"key":"7983_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101567","volume":"8","author":"M Ducreux","year":"2023","unstructured":"Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO\/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open. 2023;8:101567. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101567.","journal-title":"ESMO Open"},{"key":"7983_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Sig Transduct Target Ther. 2025;10:35 https:\/\/doi.org\/10.1038\/s41392-024-02075-w.","journal-title":"Sig Transduct Target Ther"},{"key":"7983_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0572-9","volume":"16","author":"K Nio","year":"2017","unstructured":"Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16:4. https:\/\/doi.org\/10.1186\/s12943-016-0572-9.","journal-title":"Mol Cancer"},{"key":"7983_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","volume":"19","author":"TK Lee","year":"2022","unstructured":"Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022;19:26\u201344. https:\/\/doi.org\/10.1038\/s41575-021-00508-3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7983_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-023-02893-w","volume":"42","author":"L Zhou","year":"2023","unstructured":"Zhou L, He L, Liu CH, Qiu H, Zheng L, Sample KM, et al. Liver cancer stem cell dissemination and metastasis: uncovering the role of NRCAM in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42:311 https:\/\/doi.org\/10.1186\/s13046-023-02893-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"7983_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03130-2","volume":"23","author":"Q Liu","year":"2023","unstructured":"Liu Q, Guo Z, Li G, Zhang Y, Liu X, Li B, et al. Cancer stem cells and their niche in cancer progression and therapy. Cancer Cell Int. 2023;23:305. https:\/\/doi.org\/10.1186\/s12935-023-03130-2.","journal-title":"Cancer Cell Int"},{"key":"7983_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Sig Transduct Target Ther. 2024;9:170 https:\/\/doi.org\/10.1038\/s41392-024-01851-y.","journal-title":"Sig Transduct Target Ther"},{"key":"7983_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh JJ, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31:617\u201339. https:\/\/doi.org\/10.1016\/j.stem.2024.04.004.","journal-title":"Cell Stem Cell"},{"key":"7983_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645\u20138. https:\/\/doi.org\/10.1038\/367645a0.","journal-title":"Nature"},{"key":"7983_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.05.076","volume":"231","author":"M Najafi","year":"2019","unstructured":"Najafi M, Mortezaee K, Ahadi R. Cancer stem cell (a)symmetry & plasticity: tumorigenesis and therapy relevance. Life Sci. 2019;231:116520. https:\/\/doi.org\/10.1016\/j.lfs.2019.05.076.","journal-title":"Life Sci"},{"key":"7983_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04848-z","volume":"13","author":"N Liang","year":"2022","unstructured":"Liang N, Yang T, Huang Q, Yu P, Liu C, Chen L, et al. Mechanism of cancer stemness maintenance in human liver cancer. Cell Death Dis. 2022;13:394. https:\/\/doi.org\/10.1038\/s41419-022-04848-z.","journal-title":"Cell Death Dis"},{"key":"7983_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2023.151321","volume":"102","author":"NM Warrier","year":"2023","unstructured":"Warrier NM, Kelkar N, Johnson CT, Govindarajan T, Prabhu V, Kumar P. Understanding cancer stem cells and plasticity: towards better therapeutics. Eur J Cell Biol. 2023;102:151321. https:\/\/doi.org\/10.1016\/j.ejcb.2023.151321.","journal-title":"Eur J Cell Biol"},{"key":"7983_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.reth.2021.01.005","volume":"17","author":"T Yasuda","year":"2021","unstructured":"Yasuda T, Ishimoto T, Baba H. Conflicting metabolic alterations in cancer stem cells and regulation by the stromal niche. Regen Ther. 2021;17:8\u201312. https:\/\/doi.org\/10.1016\/j.reth.2021.01.005.","journal-title":"Regen Ther"},{"key":"7983_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05929-3","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Peng X, He G, Liu J, Li X, Lin W, et al. Crosstalk between autophagy and CSCs: molecular mechanisms and translational implications. Cell Death Dis. 2023;14:409. https:\/\/doi.org\/10.1038\/s41419-023-05929-3.","journal-title":"Cell Death Dis"},{"key":"7983_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102692","volume":"62","author":"RGA Costa","year":"2023","unstructured":"Costa RGA, Silva SLR, Dias IRSB, Oliveira MS, Rodrigues ACBDC, Dias RB, et al. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. Redox Biol. 2023;62:102692. https:\/\/doi.org\/10.1016\/j.redox.2023.102692.","journal-title":"Redox Biol"},{"key":"7983_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13287-022-02856-6","volume":"13","author":"H Rezayatmand","year":"2022","unstructured":"Rezayatmand H, Razmkhah M, Razeghian-Jahromi I. Drug resistance in cancer therapy: the Pandora\u2019s Box of cancer stem cells. Stem Cell Res Ther. 2022;13:181 https:\/\/doi.org\/10.1186\/s13287-022-02856-6.","journal-title":"Stem Cell Res Ther"},{"key":"7983_CR30","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1742-1241.2008.01777.x","volume":"62","author":"W Song","year":"2008","unstructured":"Song W, Li H, Tao K, Li R, Song Z, Zhao Q, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pr. 2008;62:1212\u20138. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01777.x.","journal-title":"Int J Clin Pr"},{"key":"7983_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3460-9","volume":"17","author":"YL Chen","year":"2017","unstructured":"Chen YL, Lin PY, Ming YZ, Huang WC, Chen RF, Chen PM, et al. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients. BMC Cancer. 2017;17:474. https:\/\/doi.org\/10.1186\/s12885-017-3460-9.","journal-title":"BMC Cancer"},{"key":"7983_CR32","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.18632\/aging.103409","volume":"12","author":"H Yu","year":"2020","unstructured":"Yu H, Zhu X, Lin H, Pan H, Zhao F, Zhu M, et al. A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma. Aging. 2020;12:12234\u201350. https:\/\/doi.org\/10.18632\/aging.103409.","journal-title":"Aging"},{"key":"7983_CR33","doi-asserted-by":"publisher","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","volume":"7","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7:e1440169 https:\/\/doi.org\/10.1080\/2162402X.2018.1440169.","journal-title":"Oncoimmunology"},{"key":"7983_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.clim.2013.07.006","volume":"149","author":"J Huang","year":"2013","unstructured":"Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3\/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 2013;149:156\u201368. https:\/\/doi.org\/10.1016\/j.clim.2013.07.006.","journal-title":"Clin Immunol"},{"key":"7983_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fonc.2017.00127","volume":"7","author":"D Kleinl\u00fctzum","year":"2017","unstructured":"Kleinl\u00fctzum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, et al. Enhancing the oncolytic activity of CD133-targeted measles virus: receptor extension or chimerism with vesicular stomatitis virus are most effective. Front Oncol. 2017;7:127 https:\/\/doi.org\/10.3389\/fonc.2017.00127.","journal-title":"Front Oncol"},{"key":"7983_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4161\/cbt.10.4.12440","volume":"10","author":"JC Sun","year":"2010","unstructured":"Sun JC, Pan K, Chen MS, Wang QJ, Wang H, Ma HQ, et al. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells. Cancer Biol Ther. 2010;10:368\u201375. https:\/\/doi.org\/10.4161\/cbt.10.4.12440.","journal-title":"Cancer Biol Ther"},{"key":"7983_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2008.01.013","volume":"13","author":"ZF Yang","year":"2008","unstructured":"Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153\u201366. https:\/\/doi.org\/10.1016\/j.ccr.2008.01.013.","journal-title":"Cancer Cell"},{"key":"7983_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.gastro.2008.12.004","volume":"136","author":"T Yamashita","year":"2009","unstructured":"Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem\/progenitor cell features. Gastroenterology. 2009;136:1012\u201324. https:\/\/doi.org\/10.1053\/j.gastro.2008.12.004.","journal-title":"Gastroenterology"},{"key":"7983_CR39","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1136\/gut.2008.176271","volume":"59","author":"XR Yang","year":"2010","unstructured":"Yang XR, Xu Y, Yu B, Zhou J, Qiu SJ, Shi GM, et al. High expression levels of putative hepatic stem\/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010;59:953\u201362. https:\/\/doi.org\/10.1136\/gut.2008.176271.","journal-title":"Gut"},{"key":"7983_CR40","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jhep.2015.07.025","volume":"63","author":"O Miltiadous","year":"2015","unstructured":"Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, et al. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. J Hepatol. 2015;63:1368\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2015.07.025.","journal-title":"J Hepatol"},{"key":"7983_CR41","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/hep.26168","volume":"57","author":"T Yamashita","year":"2013","unstructured":"Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57:1484\u201397. https:\/\/doi.org\/10.1002\/hep.26168.","journal-title":"Hepatology"},{"key":"7983_CR42","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/biom12050668","volume":"12","author":"P Ye","year":"2022","unstructured":"Ye P, Chi X, Yan X, Wu F, Liang Z, Yang WH. Alanine-glyoxylate aminotransferase sustains cancer stemness properties through the upregulation of SOX2 and OCT4 in hepatocellular carcinoma cells. Biomolecules. 2022;12:668. https:\/\/doi.org\/10.3390\/biom12050668.","journal-title":"Biomolecules"},{"key":"7983_CR43","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1111\/liv.15412","volume":"42","author":"J Chen","year":"2022","unstructured":"Chen J, Li H, Zhang B, Xiong Z, Jin Z, Chen J, et al. ABI2-mediated MEOX2\/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence. Liver Int. 2022;42:2562\u201376. https:\/\/doi.org\/10.1111\/liv.15412.","journal-title":"Liver Int"},{"key":"7983_CR44","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/hep.26159","volume":"57","author":"T Oikawa","year":"2013","unstructured":"Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013;57:1469\u201383. https:\/\/doi.org\/10.1002\/hep.26159.","journal-title":"Hepatology"},{"key":"7983_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s13046-019-1508-1","volume":"38","author":"X Wang","year":"2019","unstructured":"Wang X, Wang R, Bai S, Xiong S, Li Y, Liu M, et al. Musashi2 contributes to the maintenance of CD44v6+ liver cancer stem cells via notch1 signaling pathway. J Exp Clin Cancer Res. 2019;38:505 https:\/\/doi.org\/10.1186\/s13046-019-1508-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"7983_CR46","doi-asserted-by":"publisher","first-page":"23405","DOI":"10.1021\/acsnano.3c04636","volume":"17","author":"M Zhu","year":"2023","unstructured":"Zhu M, Fan H, Deng J, Jiang K, Liao J, Zhang X, et al. BMI1 silencing liposomes suppress postradiotherapy cancer stemness against radioresistant hepatocellular carcinoma. ACS Nano. 2023;17:23405\u201321. https:\/\/doi.org\/10.1021\/acsnano.3c04636.","journal-title":"ACS Nano"},{"key":"7983_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13046-024-03021-y","volume":"43","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Zhang Y. Transcriptional regulation of cancer stem cell: regulatory factors elucidation and cancer treatment strategies. J Exp Clin Cancer Res. 2024;43:99. https:\/\/doi.org\/10.1186\/s13046-024-03021-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"7983_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Sig Transduct Target Ther. 2020;5:8. https:\/\/doi.org\/10.1038\/s41392-020-0110-5.","journal-title":"Sig Transduct Target Ther"},{"key":"7983_CR49","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/cac2.12235","volume":"41","author":"VR Silva","year":"2021","unstructured":"Silva VR, Santos LS, Dias RB, Quadros CA, Bezerra DP. Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells. Cancer Commun. 2021;41:1275\u2013313. https:\/\/doi.org\/10.1002\/cac2.12235.","journal-title":"Cancer Commun"},{"key":"7983_CR50","doi-asserted-by":"publisher","first-page":"103277","DOI":"10.1016\/j.critrevonc.2021.103277","volume":"160","author":"ACBDC Rodrigues","year":"2021","unstructured":"Rodrigues ACBDC, Costa RGA, Silva SLR, Dias IRSB, Dias RB, Bezerra DP. Cell signaling pathways as molecular targets to eliminate AML stem cells. Crit Rev Oncol Hematol. 2021;160:103277. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103277.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7983_CR51","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1016\/j.ymthe.2018.09.012","volume":"26","author":"MM Rodr\u00edguez","year":"2018","unstructured":"Rodr\u00edguez MM, Fiore E, Bayo J, Atorrasagasti C, Garc\u00eda M, Onorato A, et al. 4Mu decreases CD47 expression on hepatic cancer stem cells and primes a potent antitumor T cell response induced by interleukin-12. Mol Ther. 2018;26:2738\u201350. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.012.","journal-title":"Mol Ther"},{"key":"7983_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85491-0","volume":"11","author":"MM Rodr\u00edguez","year":"2021","unstructured":"Rodr\u00edguez MM, Onorato A, Cantero MJ, Dom\u00ednguez L, Bayo J, Fiore E, et al. 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Sci Rep. 2021;11:6310. https:\/\/doi.org\/10.1038\/s41598-021-85491-0.","journal-title":"Sci Rep"},{"key":"7983_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40436-6","volume":"9","author":"CHC Sukowati","year":"2019","unstructured":"Sukowati CHC, Anfuso B, Fiore E, Ie SI, Raseni A, Vascotto F, et al. Hyaluronic acid inhibition by 4-methylumbelliferone reduces the expression of cancer stem cells markers during hepatocarcinogenesis. Sci Rep. 2019;9:4026. https:\/\/doi.org\/10.1038\/s41598-019-40436-6.","journal-title":"Sci Rep"},{"key":"7983_CR54","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-12-3801","volume":"73","author":"T Hiraga","year":"2013","unstructured":"Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013;73:4112\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3801.","journal-title":"Cancer Res"},{"key":"7983_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66914-0","volume":"14","author":"MA D\u00edaz","year":"2024","unstructured":"D\u00edaz MA, Fusco M, Ben\u00edtez CA, Gayet F, Garc\u00eda L, Victoria L, et al. Targeting hyaluronan metabolism-related molecules associated with resistant tumor-initiating cells potentiates chemotherapy efficacy in lung cancer. Sci Rep. 2024;14:16803. https:\/\/doi.org\/10.1038\/s41598-024-66914-0.","journal-title":"Sci Rep"},{"key":"7983_CR56","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.3390\/cells11233780","volume":"11","author":"K Hasegawa","year":"2022","unstructured":"Hasegawa K, Saga R, Ohuchi K, Kuwahara Y, Tomita K, Okumura K, et al. 4-methylumebelliferone enhances radiosensitizing effects of radioresistant oral squamous cell carcinoma cells via hyaluronan synthase 3 suppression. Cells. 2022;11:3780. https:\/\/doi.org\/10.3390\/cells11233780.","journal-title":"Cells"},{"key":"7983_CR57","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3390\/cancers11081187","volume":"11","author":"NA Lokman","year":"2019","unstructured":"Lokman NA, Price ZK, Hawkins EK, Macpherson AM, Oehler MK, Ricciardelli C. 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers. 2019;11:1187. https:\/\/doi.org\/10.3390\/cancers11081187.","journal-title":"Cancers"},{"key":"7983_CR58","doi-asserted-by":"publisher","first-page":"13939","DOI":"10.1021\/acs.jafc.9b05733","volume":"67","author":"Q Kang","year":"2019","unstructured":"Kang Q, Gong J, Wang M, Wang Q, Chen F, Cheng KW. 6-C-(E-Phenylethenyl)Naringenin attenuates the stemness of hepatocellular carcinoma cells by suppressing Wnt\/\u03b2-catenin signaling. J Agric Food Chem. 2019;67:13939\u201347. https:\/\/doi.org\/10.1021\/acs.jafc.9b05733.","journal-title":"J Agric Food Chem"},{"key":"7983_CR59","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1073\/pnas.1802279115","volume":"115","author":"XY Qin","year":"2018","unstructured":"Qin XY, Suzuki H, Honda M, Okada H, Kaneko S, Inoue I, et al. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. Proc Natl Acad Sci USA. 2018;115:4969\u201374. https:\/\/doi.org\/10.1073\/pnas.1802279115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7983_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05847-4","volume":"14","author":"XY Qin","year":"2023","unstructured":"Qin XY, Furutani Y, Yonezawa K, Shimizu N, Kato-Murayama M, Shirouzu M, et al. Targeting transglutaminase 2 mediated exostosin glycosyltransferase 1 signaling in liver cancer stem cells with acyclic retinoid. Cell Death Dis. 2023;14:358. https:\/\/doi.org\/10.1038\/s41419-023-05847-4.","journal-title":"Cell Death Dis"},{"key":"7983_CR61","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13287-015-0046-9","volume":"6","author":"HB Guan","year":"2015","unstructured":"Guan HB, Nie YZ, Zheng YW, Takiguchi K, Yu HW, Zhang RR, et al. Acyclic retinoid induces differentiation and apoptosis of murine hepatic stem cells. Stem Cell Res Ther. 2015;6:51. https:\/\/doi.org\/10.1186\/s13287-015-0046-9.","journal-title":"Stem Cell Res Ther"},{"key":"7983_CR62","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.30071","volume":"68","author":"R Wu","year":"2018","unstructured":"Wu R, Murali R, Kabe Y, French SW, Chiang YM, Liu S, et al. Baicalein targets GTPase-mediated autophagy to eliminate liver tumor-initiating stem cell-like cells resistant to mTORC1 inhibition. Hepatology. 2018;68:1726\u201340. https:\/\/doi.org\/10.1002\/hep.30071.","journal-title":"Hepatology"},{"key":"7983_CR63","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/abbs\/gmy045","volume":"50","author":"L Song","year":"2018","unstructured":"Song L, Chen X, Wang P, Gao S, Qu C, Liu L. Effects of baicalein on pancreatic cancer stem cells via modulation of sonic Hedgehog pathway. Acta Biochim Biophys Sin. 2018;50:586\u201396. https:\/\/doi.org\/10.1093\/abbs\/gmy045.","journal-title":"Acta Biochim Biophys Sin"},{"key":"7983_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.biocel.2017.08.015","volume":"91","author":"RS Patwardhan","year":"2017","unstructured":"Patwardhan RS, Pal D, Checker R, Sharma D, Sandur SK. Baicalein induces cell death in murine T cell lymphoma via inhibition of thioredoxin system. Int J Biochem Cell Biol. 2017;91:45\u201352. https:\/\/doi.org\/10.1016\/j.biocel.2017.08.015.","journal-title":"Int J Biochem Cell Biol"},{"key":"7983_CR65","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3892\/mmr.2020.11051","volume":"21","author":"Q Zeng","year":"2020","unstructured":"Zeng Q, Zhang Y, Zhang W, Guo Q. Baicalein suppresses the proliferation and invasiveness of colorectal cancer cells by inhibiting Snail-induced epithelial-mesenchymal transition. Mol Med Rep. 2020;21:2544\u201352. https:\/\/doi.org\/10.3892\/mmr.2020.11051.","journal-title":"Mol Med Rep"},{"key":"7983_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/ijo.2016.3496","volume":"49","author":"M Yamashita","year":"2016","unstructured":"Yamashita M, Wada H, Eguchi H, Ogawa H, Yamada D, Noda T, et al. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Int J Oncol. 2016;49:89\u201398. https:\/\/doi.org\/10.3892\/ijo.2016.3496.","journal-title":"Int J Oncol"},{"key":"7983_CR67","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1172\/JCI42550","volume":"120","author":"N Haraguchi","year":"2010","unstructured":"Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120:3326\u201339. https:\/\/doi.org\/10.1172\/JCI42550.","journal-title":"J Clin Invest"},{"key":"7983_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.233","volume":"10","author":"B Hu","year":"2020","unstructured":"Hu B, Xu Y, Li YC, Huang JF, Cheng JW, Guo W, et al. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-\u03baB oncogenic signaling. Clin Transl Med. 2020;10:e233. https:\/\/doi.org\/10.1002\/ctm2.233.","journal-title":"Clin Transl Med"},{"key":"7983_CR69","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/labinvest.2012.65","volume":"92","author":"I Martin-Padura","year":"2012","unstructured":"Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest. 2012;92:952\u201366. https:\/\/doi.org\/10.1038\/labinvest.2012.65.","journal-title":"Lab Invest"},{"key":"7983_CR70","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41388-018-0406-x","volume":"38","author":"R Toshiyama","year":"2019","unstructured":"Toshiyama R, Konno M, Eguchi H, Takemoto H, Noda T, Asai A, et al. Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells. Oncogene. 2019;38:244\u201360. https:\/\/doi.org\/10.1038\/s41388-018-0406-x.","journal-title":"Oncogene"},{"key":"7983_CR71","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3892\/ijo.2017.4159","volume":"51","author":"C Dou","year":"2017","unstructured":"Dou C, Fang C, Zhao Y, Fu X, Zhang Y, Zhu D, et al. BC-02 eradicates liver cancer stem cells by upregulating the ROS-dependent DNA damage. Int J Oncol. 2017;51:1775\u201384. https:\/\/doi.org\/10.3892\/ijo.2017.4159.","journal-title":"Int J Oncol"},{"key":"7983_CR72","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3389\/fphar.2018.01042","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang J, Fang C, Qu M, Wu H, Wang X, Zhang H, et al. CD13 inhibition enhances cytotoxic effect of chemotherapy agents. Front Pharm. 2018;9:1042. https:\/\/doi.org\/10.3389\/fphar.2018.01042.","journal-title":"Front Pharm"},{"key":"7983_CR73","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1567-5769(03)00083-3","volume":"3","author":"T Fujisaki","year":"2003","unstructured":"Fujisaki T, Otsuka T, Gondo H, Okamura T, Niho Y, Ohhinata A, et al. Bestatin selectively suppresses the growth of leukemic stem\/progenitor cells with BCR\/ABL mRNA transcript in patients with chronic myelogeneous leukemia. Int Immunopharmacol. 2003;3:901\u20137. https:\/\/doi.org\/10.1016\/S1567-5769(03)00083-3.","journal-title":"Int Immunopharmacol"},{"key":"7983_CR74","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12672-024-01063-4","volume":"15","author":"Y Ma","year":"2024","unstructured":"Ma Y, Yang X, Pan P, Yang J, Wu X, Wang D, et al. Bestatin attenuates breast cancer stemness by targeting puromycin-sensitive aminopeptidase. Discov Oncol. 2024;15:197. https:\/\/doi.org\/10.1007\/s12672-024-01063-4.","journal-title":"Discov Oncol"},{"key":"7983_CR75","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jhep.2015.04.018","volume":"63","author":"JU Marquardt","year":"2015","unstructured":"Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, et al. Curcumin effectively inhibits oncogenic NF-\u03baB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63:661\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.018.","journal-title":"J Hepatol"},{"key":"7983_CR76","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.3892\/etm.2018.5805","volume":"15","author":"J Wang","year":"2018","unstructured":"Wang J, Wang C, Bu G. Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin signaling pathway. Exp Ther Med. 2018;15:3650\u20138. https:\/\/doi.org\/10.3892\/etm.2018.5805.","journal-title":"Exp Ther Med"},{"key":"7983_CR77","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s11418-021-01505-1","volume":"75","author":"X Mao","year":"2021","unstructured":"Mao X, Zhang X, Zheng X, Chen Y, Xuan Z, Huang P. Curcumin suppresses LGR5(+) colorectal cancer stem cells by inducing autophagy and via repressing TFAP2A-mediated ECM pathway. J Nat Med. 2021;75:590\u2013601. https:\/\/doi.org\/10.1007\/s11418-021-01505-1.","journal-title":"J Nat Med"},{"key":"7983_CR78","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1055\/a-1867-4805","volume":"72","author":"MA Vatankhah","year":"2022","unstructured":"Vatankhah MA, Panahizadeh R, Nejati-Koshki K, Arabzadeh M, Arabzadeh AA, Najafzadeh N. Curcumin upregulates miR-148a to increase the chemosensitivity of CD44-positive prostate cancer stem cells to paclitaxel through targeting the MSK1\/IRS1 axis. Drug Res. 2022;72:457\u201365. https:\/\/doi.org\/10.1055\/a-1867-4805.","journal-title":"Drug Res"},{"key":"7983_CR79","doi-asserted-by":"publisher","first-page":"251","DOI":"10.24976\/Discov.Med.202335176.26","volume":"35","author":"J Zhou","year":"2023","unstructured":"Zhou J, Zhang L, Yan J, Hou A, Sui W, Sun M. Curcumin Induces Ferroptosis in A549 CD133+ Cells through the GSH-GPX4 and FSP1-CoQ10-NAPH Pathways. Discov Med. 2023;35:251\u201363. https:\/\/doi.org\/10.24976\/Discov.Med.202335176.26.","journal-title":"Discov Med"},{"key":"7983_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0453-3","volume":"17","author":"QM Zhou","year":"2017","unstructured":"Zhou QM, Sun Y, Lu YY, Zhang H, Chen QL, Su SB. Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis. Cancer Cell Int. 2017;17:84. https:\/\/doi.org\/10.1186\/s12935-017-0453-3.","journal-title":"Cancer Cell Int"},{"key":"7983_CR81","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.ajpath.2016.04.011","volume":"186","author":"K Kawaguchi","year":"2016","unstructured":"Kawaguchi K, Honda M, Yamashita T, Okada H, Shirasaki T, Nishikawa M, et al. Jagged1 DNA Copy Number Variation Is Associated with Poor Outcome in Liver Cancer. Am J Pathol. 2016;186:2055\u201367. https:\/\/doi.org\/10.1016\/j.ajpath.2016.04.011.","journal-title":"Am J Pathol"},{"key":"7983_CR82","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1158\/1535-7163.MCT-19-0004","volume":"18","author":"DC Kahraman","year":"2019","unstructured":"Kahraman DC, Kahraman T, Cetin-Atalay R. Targeting PI3K\/Akt\/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment. Mol Cancer Ther. 2019;18:2146\u201357. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0004.","journal-title":"Mol Cancer Ther"},{"key":"7983_CR83","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbrc.2020.03.009","volume":"525","author":"H Hemati","year":"2020","unstructured":"Hemati H, Kaur J, Sobti RC, Trehanpati N. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133+ cells to vincristine and 5-fluorouracil through upregulation of BBC3. Biochem Biophys Res Commun. 2020;525:941\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2020.03.009.","journal-title":"Biochem Biophys Res Commun"},{"key":"7983_CR84","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11670-011-0140-1","volume":"23","author":"LY Jiang","year":"2011","unstructured":"Jiang LY, Zhang XL, Du P, Zheng JH. \u03b3-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro. Chin J Cancer Res. 2011;23:140\u20136. https:\/\/doi.org\/10.1007\/s11670-011-0140-1.","journal-title":"Chin J Cancer Res"},{"key":"7983_CR85","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.18632\/oncotarget.23156","volume":"9","author":"M Ikram","year":"2017","unstructured":"Ikram M, Lim Y, Baek SY, Jin S, Jeong YH, Kwak JY, et al. Co-targeting of Tiam1\/Rac1 and Notch ameliorates chemoresistance against doxorubicin in a biomimetic 3D lymphoma model. Oncotarget. 2017;9:2058\u201375. https:\/\/doi.org\/10.18632\/oncotarget.23156.","journal-title":"Oncotarget"},{"key":"7983_CR86","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1995-7645(14)60092-4","volume":"7","author":"X Liu","year":"2014","unstructured":"Liu X, Xu QR, Xie WF, Wang MD. DAPT suppresses the proliferation of human glioma cell line SHG-44. Asian Pac J Trop Med. 2014;7:552\u20136. https:\/\/doi.org\/10.1016\/S1995-7645(14)60092-4.","journal-title":"Asian Pac J Trop Med"},{"key":"7983_CR87","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1541-7786.MCR-10-0457","volume":"9","author":"PM McGowan","year":"2011","unstructured":"McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, et al. Notch1 inhibition alters the CD44hi\/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res. 2011;9:834\u201344. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0457.","journal-title":"Mol Cancer Res"},{"key":"7983_CR88","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.4103\/jcrt.JCRT_482_17","volume":"15","author":"H Cai","year":"2019","unstructured":"Cai H, Lu W, Zhang Y, Liu H, Wang Z, Shen Y. Specific inhibition of Notch1 signaling suppresses properties of lung cancer stem cells. J Cancer Res Ther. 2019;15:1547\u201352. https:\/\/doi.org\/10.4103\/jcrt.JCRT_482_17.","journal-title":"J Cancer Res Ther"},{"key":"7983_CR89","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.3892\/ol.2015.3727","volume":"10","author":"LC Li","year":"2015","unstructured":"Li LC, Wang DL, Wu YZ, Nian WQ, Wu ZJ, Li Y, et al. Gastric tumor-initiating CD44+ cells and epithelial-mesenchymal transition are inhibited by \u03b3-secretase inhibitor DAPT. Oncol Lett. 2015;10:3293\u20139. https:\/\/doi.org\/10.3892\/ol.2015.3727.","journal-title":"Oncol Lett"},{"key":"7983_CR90","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.21873\/anticanres.11727","volume":"37","author":"K Seto","year":"2017","unstructured":"Seto K, Sakabe T, Itaba N, Azumi J, Oka H, Morimoto M, et al. A novel small-molecule WNT inhibitor, IC-2, has the potential to suppress liver cancer stem cells. Anticancer Res. 2017;37:3569\u201379. https:\/\/doi.org\/10.21873\/anticanres.11727.","journal-title":"Anticancer Res"},{"key":"7983_CR91","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.21873\/anticanres.11795","volume":"37","author":"S Urushibara","year":"2017","unstructured":"Urushibara S, Tsubota T, Asai R, Azumi J, Ashida K, Fujiwara Y, et al. WNT\/\u03b2-catenin signaling inhibitor IC-2 suppresses sphere formation and sensitizes colorectal cancer cells to 5-fluorouracil. Anticancer Res. 2017;37:4085\u201391. https:\/\/doi.org\/10.21873\/anticanres.11795.","journal-title":"Anticancer Res"},{"key":"7983_CR92","first-page":"93","volume":"59","author":"S Yokogi","year":"2016","unstructured":"Yokogi S, Tsubota T, Kanki K, Azumi J, Itaba N, Oka H, et al. Wnt\/Beta-catenin signal inhibitor HC-1 sensitizes oral squamous cell carcinoma cells to 5-fluorouracil through reduction of CD44-positive population. Yonago Acta Med. 2016;59:93\u20139.","journal-title":"Yonago Acta Med"},{"key":"7983_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113489","volume":"221","author":"K \u0130bi\u015f","year":"2021","unstructured":"\u0130bi\u015f K, Nalbat E, \u00c7al\u0131\u015fkan B, Kahraman DC, Cetin-Atalay R, Banoglu E. Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells. Eur J Med Chem. 2021;221:113489. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113489.","journal-title":"Eur J Med Chem"},{"key":"7983_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2021.05.003","volume":"513","author":"Z Liang","year":"2021","unstructured":"Liang Z, Wu B, Ji Z, Liu W, Shi D, Chen X, et al. The binding of LDN193189 to CD133 C-terminus suppresses the tumorigenesis and immune escape of liver tumor-initiating cells. Cancer Lett. 2021;513:90\u2013100. https:\/\/doi.org\/10.1016\/j.canlet.2021.05.003.","journal-title":"Cancer Lett"},{"key":"7983_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.113071","volume":"222","author":"Y Wang","year":"2023","unstructured":"Wang Y, Ma S, Liu X, Wei Y, Xu H, Liang Z, et al. Hyaluronic acid mediated Fe3O4 nanocubes reversing the EMT through targeted cancer stem cell. Colloids Surf B Biointerfaces. 2023;222:113071. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.113071.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"7983_CR96","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/0008-5472.CAN-12-2862","volume":"73","author":"AL Balboni","year":"2013","unstructured":"Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, et al. \u0394Np63\u03b1-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res. 2013;73:1020\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2862.","journal-title":"Cancer Res"},{"key":"7983_CR97","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3390\/cancers14092095","volume":"14","author":"D Filipponi","year":"2022","unstructured":"Filipponi D, Pagnuzzi-Boncompagni M, Pag\u00e8s G. Inhibiting ALK2\/ALK3 signaling to differentiate and chemo-sensitize medulloblastoma. Cancers. 2022;14:2095. https:\/\/doi.org\/10.3390\/cancers14092095.","journal-title":"Cancers"},{"key":"7983_CR98","doi-asserted-by":"publisher","first-page":"7882","DOI":"10.3390\/ijms22157882","volume":"22","author":"T Fukuda","year":"2021","unstructured":"Fukuda T, Fukuda R, Miyazono K, Heldin CH. Tumor promoting effect of BMP signaling in endometrial cancer. Int J Mol Sci. 2021;22:7882. https:\/\/doi.org\/10.3390\/ijms22157882.","journal-title":"Int J Mol Sci"},{"key":"7983_CR99","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hep.24000","volume":"53","author":"TK Lee","year":"2011","unstructured":"Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology. 2011;53:160\u201370. https:\/\/doi.org\/10.1002\/hep.24000.","journal-title":"Hepatology"},{"key":"7983_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2023.116699","volume":"478","author":"MA Khan","year":"2023","unstructured":"Khan MA, Singh D, Jameel M, Maurya SK, Singh S, Akhtar K, et al. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy. Toxicol Appl Pharm. 2023;478:116699. https:\/\/doi.org\/10.1016\/j.taap.2023.116699.","journal-title":"Toxicol Appl Pharm"},{"key":"7983_CR101","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jpp\/rgab060","volume":"74","author":"S Che","year":"2022","unstructured":"Che S, Wu S, Yu P. Lupeol induces autophagy and apoptosis with reduced cancer stem-like properties in retinoblastoma via phosphoinositide 3-kinase\/protein kinase B\/mammalian target of rapamycin inhibition. J Pharm Pharm. 2022;74:208\u201315. https:\/\/doi.org\/10.1093\/jpp\/rgab060.","journal-title":"J Pharm Pharm"},{"key":"7983_CR102","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.mvr.2018.10.008","volume":"121","author":"S Bhattacharyya","year":"2019","unstructured":"Bhattacharyya S, Mitra D, Ray S, Biswas N, Banerjee S, Majumder B, et al. Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression. Microvasc Res. 2019;121:52\u201362. https:\/\/doi.org\/10.1016\/j.mvr.2018.10.008.","journal-title":"Microvasc Res"},{"key":"7983_CR103","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.23812\/j.biol.regul.homeost.agents.20233703.130","volume":"37","author":"L Huang","year":"2023","unstructured":"Huang L, Zhao Z, Li C. Lupeol inhibits stemness in colon cancer-stem like cells and promotes chemosensitivity via degrading \u03b2-catenin. J Biol Regul Homeost Agents. 2023;37:1293\u2013302. https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.20233703.130.","journal-title":"J Biol Regul Homeost Agents"},{"key":"7983_CR104","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40360-022-00589-z","volume":"23","author":"D Li","year":"2022","unstructured":"Li D, Zhang Q, Zhou Y, Zhu H, Li T, Du F. A novel nitidine chloride nanoparticle overcomes the stemness of CD133+EPCAM+ Huh7 hepatocellular carcinoma cells for liver cancer therapy. BMC Pharm Toxicol. 2022;23:48. https:\/\/doi.org\/10.1186\/s40360-022-00589-z.","journal-title":"BMC Pharm Toxicol"},{"key":"7983_CR105","doi-asserted-by":"publisher","first-page":"591","DOI":"10.21037\/atm-20-3432","volume":"8","author":"H Gong","year":"2020","unstructured":"Gong H, Wang L, Zhao J, Wang L, Yu Q, Wan Y. Nitidine chloride inhibits the appearance of cancer stem-like properties and regulates potential the mitochondrial membrane alterations of colon cancer cells. Ann Transl Med. 2020;8:591. https:\/\/doi.org\/10.21037\/atm-20-3432.","journal-title":"Ann Transl Med"},{"key":"7983_CR106","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1002\/cam4.3869","volume":"10","author":"M Jia","year":"2021","unstructured":"Jia M, Wang Y, Guo Y, Yu P, Sun Y, Song Y, et al. Nitidine chloride suppresses epithelial-mesenchymal transition and stem cell-like properties in glioblastoma by regulating JAK2\/STAT3 signaling. Cancer Med. 2021;10:3113\u201328. https:\/\/doi.org\/10.1002\/cam4.3869.","journal-title":"Cancer Med"},{"key":"7983_CR107","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13578-016-0104-8","volume":"6","author":"M Sun","year":"2016","unstructured":"Sun M, Zhang N, Wang X, Li Y, Qi W, Zhang H, et al. Hedgehog pathway is involved in nitidine chloride induced inhibition of epithelial-mesenchymal transition and cancer stem cells-like properties in breast cancer cells. Cell Biosci. 2016;6:44. https:\/\/doi.org\/10.1186\/s13578-016-0104-8.","journal-title":"Cell Biosci"},{"key":"7983_CR108","doi-asserted-by":"publisher","first-page":"42923","DOI":"10.18632\/oncotarget.5976","volume":"6","author":"WC Chen","year":"2015","unstructured":"Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho CY, et al. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. 2015;6:42923\u201337. https:\/\/doi.org\/10.18632\/oncotarget.5976.","journal-title":"Oncotarget"},{"key":"7983_CR109","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201166","volume":"9","author":"JN Zhou","year":"2022","unstructured":"Zhou JN, Zhang B, Wang HY, Wang DX, Zhang MM, Zhang M, et al. A functional screening identifies a new organic selenium compound targeting cancer stem cells: role of c-Myc transcription activity inhibition in liver cancer. Adv Sci. 2022;9:e2201166. https:\/\/doi.org\/10.1002\/advs.202201166.","journal-title":"Adv Sci"},{"key":"7983_CR110","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4031008","volume":"2022","author":"M Liao","year":"2022","unstructured":"Liao M, Du H, Wang B, Huang J, Huang D, Tong G. Anticancer effect of polyphyllin I in suppressing stem cell-like properties of hepatocellular carcinoma via the AKT\/GSK-3\u03b2\/\u03b2-catenin signaling pathway. Oxid Med Cell Longev. 2022;2022:4031008. https:\/\/doi.org\/10.1155\/2022\/4031008.","journal-title":"Oxid Med Cell Longev"},{"key":"7983_CR111","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1568009623666221024103834","volume":"23","author":"L Xu","year":"2023","unstructured":"Xu L, Chen Z, Wang Y, Li Y, Wang Z, Li F, et al. Polyphyllin VII as a potential drug for targeting stemness in hepatocellular cancer via STAT3 signaling. Current Cancer Drug Targets. 2023;23:325\u201331. https:\/\/doi.org\/10.2174\/1568009623666221024103834.","journal-title":"Current Cancer Drug Targets"},{"key":"7983_CR112","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2174\/1568009622666220304110222","volume":"22","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Fu F, Wang Z, Qiu F, Deng T, Du B, et al. Polyphyllin VII is a potential drug targeting CD44 positive colon cancer cells. Curr Cancer Drug Targets. 2022;22:426\u201335. https:\/\/doi.org\/10.2174\/1568009622666220304110222.","journal-title":"Curr Cancer Drug Targets"},{"key":"7983_CR113","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13046-019-1163-6","volume":"38","author":"L Sun","year":"2019","unstructured":"Sun L, Wang Y, Wang L, Yao B, Chen T, Li Q, et al. Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP. J Exp Clin Cancer Res. 2019;38:170. https:\/\/doi.org\/10.1186\/s13046-019-1163-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"7983_CR114","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-017-0501-x","volume":"12","author":"M Bartucci","year":"2017","unstructured":"Bartucci M, Hussein MS, Huselid E, Flaherty K, Patrizii M, Laddha SV, et al. Synthesis and characterization of novel BMI1 inhibitors targeting cellular self-renewal in hepatocellular carcinoma. Target Oncol. 2017;12:449\u201362. https:\/\/doi.org\/10.1007\/s11523-017-0501-x.","journal-title":"Target Oncol"},{"key":"7983_CR115","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41420-024-02036-w","volume":"10","author":"LM Bomfim","year":"2024","unstructured":"Bomfim LM, Neves SP, Coelho AMRM, Nogueira ML, Dias RB, Valverde LF, et al. Ru(II)-based complexes containing 2-thiouracil derivatives suppress liver cancer stem cells by targeting NF-\u03baB and Akt\/mTOR signaling. Cell Death Discov. 2024;10:270. https:\/\/doi.org\/10.1038\/s41420-024-02036-w.","journal-title":"Cell Death Discov"},{"key":"7983_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117059","volume":"177","author":"SP Neves","year":"2024","unstructured":"Neves SP, Bomfim LM, Kataura T, Carvalho SG, Nogueira ML, Dias RB, et al. Ruthenium complex containing 1,3-thiazolidine-2-thione inhibits hepatic cancer stem cells by suppressing Akt\/mTOR signalling and leading to apoptotic and autophagic cell death. Biomed Pharmacother. 2024;177:117059. https:\/\/doi.org\/10.1016\/j.biopha.2024.117059.","journal-title":"Biomed Pharmacother"},{"key":"7983_CR117","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3389\/fonc.2019.00562","volume":"9","author":"SP Neves","year":"2019","unstructured":"Neves SP, de Carvalho NC, da Silva MM, Rodrigues ACBC, Bomfim LM, Dias RB, et al. Ruthenium complexes containing heterocyclic thioamidates trigger caspase-mediated apoptosis through MAPK signaling in human hepatocellular carcinoma cells. Front Oncol. 2019;9:562. https:\/\/doi.org\/10.3389\/fonc.2019.00562.","journal-title":"Front Oncol"},{"key":"7983_CR118","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","volume":"138","author":"PB Gupta","year":"2009","unstructured":"Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645\u201359. https:\/\/doi.org\/10.1016\/j.cell.2009.06.034.","journal-title":"Cell"},{"key":"7983_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tox.2017.04.006","volume":"384","author":"J Sun","year":"2017","unstructured":"Sun J, Luo Q, Liu L, Yang X, Zhu S, Song G. Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1\/2 signalling pathway. Toxicology. 2017;384:1\u201310. https:\/\/doi.org\/10.1016\/j.tox.2017.04.006.","journal-title":"Toxicology"},{"key":"7983_CR120","doi-asserted-by":"publisher","first-page":"630","DOI":"10.2174\/1574888X15666200123121225","volume":"16","author":"Q Liu","year":"2021","unstructured":"Liu Q, Sun J, Luo Q, Ju Y, Song G. Salinomycin suppresses tumorigenicity of liver cancer stem cells and Wnt\/Beta-catenin signaling. Curr Stem Cell Res Ther. 2021;16:630\u20137. https:\/\/doi.org\/10.2174\/1574888X15666200123121225.","journal-title":"Curr Stem Cell Res Ther"},{"key":"7983_CR121","doi-asserted-by":"publisher","first-page":"e50638","DOI":"10.1371\/journal.pone.0050638","volume":"7","author":"F Wang","year":"2012","unstructured":"Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, et al. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 2012;7:e50638. https:\/\/doi.org\/10.1371\/journal.pone.0050638.","journal-title":"PLoS One"},{"key":"7983_CR122","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3892\/ol.2018.9796","volume":"17","author":"C Fu","year":"2019","unstructured":"Fu C, Wang L, Tian G, Zhang C, Zhao Y, Xu H, et al. Enhanced anticancer effect of oncostatin M combined with salinomycin in CD133+ HepG2 liver cancer cells. Oncol Lett. 2019;17:1798\u2013806. https:\/\/doi.org\/10.3892\/ol.2018.9796.","journal-title":"Oncol Lett"},{"key":"7983_CR123","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.2217\/nnm.15.106","volume":"10","author":"X Mao","year":"2015","unstructured":"Mao X, Liu J, Gong Z, Zhang H, Lu Y, Zou H, et al. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine. 2015;10:2677\u201395. https:\/\/doi.org\/10.2217\/nnm.15.106.","journal-title":"Nanomedicine"},{"key":"7983_CR124","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.2217\/nnm-2016-0137","volume":"11","author":"Z Gong","year":"2016","unstructured":"Gong Z, Chen D, Xie F, Liu J, Zhang H, Zou H, et al. Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells. Nanomedicine. 2016;11:2565\u201379. https:\/\/doi.org\/10.2217\/nnm-2016-0137.","journal-title":"Nanomedicine"},{"key":"7983_CR125","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2217\/nnm-2016-0125","volume":"11","author":"F Xie","year":"2016","unstructured":"Xie F, Zhang S, Liu J, Gong Z, Yang K, Zhang H, et al. Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. Nanomedicine. 2016;11:1831\u201346. https:\/\/doi.org\/10.2217\/nnm-2016-0125.","journal-title":"Nanomedicine"},{"key":"7983_CR126","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2217\/nnm-2016-0408","volume":"12","author":"M Wang","year":"2017","unstructured":"Wang M, Xie F, Wen X, Chen H, Zhang H, Liu J, et al. Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells. Nanomedicine. 2017;12:1025\u201342. https:\/\/doi.org\/10.2217\/nnm-2016-0408.","journal-title":"Nanomedicine"},{"key":"7983_CR127","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.2147\/IJN.S236928","volume":"15","author":"J Wang","year":"2020","unstructured":"Wang J, Zhuo J, Tao Y, Xu S, Chen Z, Yang F, et al. Salinomycin-loaded small-molecule nanoprodrugs enhance anticancer activity in hepatocellular carcinoma. Int J Nanomed. 2020;15:6839\u201354. https:\/\/doi.org\/10.2147\/IJN.S236928.","journal-title":"Int J Nanomed"},{"key":"7983_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113865","volume":"434","author":"B Zhang","year":"2024","unstructured":"Zhang B, Ding Z, Wen X, Song G, Luo Q. Salinomycin and IR780-loaded upconversion nanoparticles influence biological behavior of liver cancer stem cells by persistently activating the MAPK signaling pathway. Exp Cell Res. 2024;434:113865. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113865.","journal-title":"Exp Cell Res"},{"key":"7983_CR129","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fchem.2020.00649","volume":"8","author":"Z Wang","year":"2020","unstructured":"Wang Z, Sun M, Li W, Fan L, Zhou Y, Hu Z. A novel CD133- and EpCAM-targeted liposome with redox-responsive properties capable of synergistically eliminating liver cancer stem cells. Front Chem. 2020;8:649. https:\/\/doi.org\/10.3389\/fchem.2020.00649.","journal-title":"Front Chem"},{"key":"7983_CR130","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/nchem.2778","volume":"9","author":"TT Mai","year":"2017","unstructured":"Mai TT, Hama\u00ef A, Hienzsch A, Ca\u00f1eque T, M\u00fcller S, Wicinski J, et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. 2017;9:1025\u201333. https:\/\/doi.org\/10.1038\/nchem.2778.","journal-title":"Nat Chem"},{"key":"7983_CR131","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bbrc.2010.03.138","volume":"394","author":"D Fuchs","year":"2010","unstructured":"Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010;394:1098\u2013104. https:\/\/doi.org\/10.1016\/j.bbrc.2010.03.138.","journal-title":"Biochem Biophys Res Commun"},{"key":"7983_CR132","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2174\/157340611794859307","volume":"7","author":"Y Wang","year":"2011","unstructured":"Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem. 2011;7:106\u201311. https:\/\/doi.org\/10.2174\/157340611794859307.","journal-title":"Med Chem"},{"key":"7983_CR133","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1245\/s10434-011-1561-2","volume":"18","author":"TT Dong","year":"2011","unstructured":"Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets \u2018CD133+\u2018 cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011;18:1797\u2013804. https:\/\/doi.org\/10.1245\/s10434-011-1561-2.","journal-title":"Ann Surg Oncol"},{"key":"7983_CR134","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2011.07.016","volume":"311","author":"QL Tang","year":"2011","unstructured":"Tang QL, Zhao ZQ, Li JC, Liang Y, Yin JQ, Zou CY, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011;311:113\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2011.07.016.","journal-title":"Cancer Lett"},{"key":"7983_CR135","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.biopha.2011.06.006","volume":"65","author":"QM Zhi","year":"2011","unstructured":"Zhi QM, Chen XH, Ji J, Zhang JN, Li JF, Cai Q, et al. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother. 2011;65:509\u201315. https:\/\/doi.org\/10.1016\/j.biopha.2011.06.006.","journal-title":"Biomed Pharmacother"},{"key":"7983_CR136","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/CAD.0000000000001311","volume":"33","author":"Z Lu","year":"2022","unstructured":"Lu Z, Zhang Z, Yang M, Xiao M. Ubiquitin-specific protease 1 inhibition sensitizes hepatocellular carcinoma cells to doxorubicin by ubiquitinated proliferating cell nuclear antigen-mediated attenuation of stemness. Anticancer Drugs. 2022;33:622\u201331. https:\/\/doi.org\/10.1097\/CAD.0000000000001311.","journal-title":"Anticancer Drugs"},{"key":"7983_CR137","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","volume":"23","author":"DS Das","year":"2017","unstructured":"Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, et al. Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells. Clin Cancer Res. 2017;23:4280\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2692.","journal-title":"Clin Cancer Res"},{"key":"7983_CR138","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jhep.2013.07.009","volume":"59","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Guan DX, Shi J, Gao H, Li JJ, Zhao JS, et al. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. J Hepatol. 2013;59:1255\u201363. https:\/\/doi.org\/10.1016\/j.jhep.2013.07.009.","journal-title":"J Hepatol"},{"key":"7983_CR139","doi-asserted-by":"publisher","first-page":"e0143255","DOI":"10.1371\/journal.pone.0143255","volume":"10","author":"X Zhu","year":"2015","unstructured":"Zhu X, Wang W, Zhang X, Bai J, Chen G, Li L, et al. All-trans retinoic acid-induced deficiency of the Wnt\/\u03b2-catenin pathway enhances hepatic carcinoma stem cell differentiation. PLoS One. 2015;10:e0143255. https:\/\/doi.org\/10.1371\/journal.pone.0143255.","journal-title":"PLoS One"},{"key":"7983_CR140","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/hep.28117","volume":"62","author":"DX Guan","year":"2015","unstructured":"Guan DX, Shi J, Zhang Y, Zhao JS, Long LY, Chen TW, et al. Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology. 2015;62:1791\u2013803. https:\/\/doi.org\/10.1002\/hep.28117.","journal-title":"Hepatology"},{"key":"7983_CR141","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00535-024-02140-9","volume":"59","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Che N, Wang S, Meng J, Zhao N, Han J, et al. Nrf2\/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia. J Gastroenterol. 2024;59:941\u201357. https:\/\/doi.org\/10.1007\/s00535-024-02140-9.","journal-title":"J Gastroenterol"},{"key":"7983_CR142","doi-asserted-by":"publisher","first-page":"28000","DOI":"10.18632\/oncotarget.8584","volume":"7","author":"Z Zheng","year":"2016","unstructured":"Zheng Z, Liu J, Yang Z, Wu L, Xie H, Jiang C, et al. MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt\/\u03b2-catenin signaling pathway. Oncotarget. 2016;7:28000\u201312. https:\/\/doi.org\/10.18632\/oncotarget.8584.","journal-title":"Oncotarget"},{"key":"7983_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06818-0","volume":"20","author":"W Yao","year":"2020","unstructured":"Yao W, Wang L, Huang H, Li X, Wang P, Mi K, et al. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. BMC Cancer. 2020;20:315. https:\/\/doi.org\/10.1186\/s12885-020-06818-0.","journal-title":"BMC Cancer"},{"key":"7983_CR144","first-page":"22","volume":"51","author":"WJ Fan","year":"2021","unstructured":"Fan WJ, Ding H, Chen XX, Yang L. All-trans retinoic acid potentiates antitumor efficacy of cisplatin by increasing differentiation of cancer stem-like cells in cervical cancer. Ann Clin Lab Sci. 2021;51:22\u201329.","journal-title":"Ann Clin Lab Sci"},{"key":"7983_CR145","first-page":"4915","volume":"30","author":"M Karsy","year":"2010","unstructured":"Karsy M, Albert L, Tobias ME, Murali R, Jhanwar-Uniyal M. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner. Anticancer Res. 2010;30:4915\u201320.","journal-title":"Anticancer Res"},{"key":"7983_CR146","doi-asserted-by":"publisher","first-page":"e0182835","DOI":"10.1371\/journal.pone.0182835","volume":"12","author":"D Mei","year":"2017","unstructured":"Mei D, Lv B, Chen B, Xiao S, Jiang J, Xie Y, et al. All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis. PLoS One. 2017;12:e0182835. https:\/\/doi.org\/10.1371\/journal.pone.0182835.","journal-title":"PLoS One"},{"key":"7983_CR147","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1016\/j.ejca.2012.04.013","volume":"48","author":"YC Lim","year":"2012","unstructured":"Lim YC, Kang HJ, Kim YS, Choi EC. All-trans-retinoic acid inhibits growth of head and neck cancer stem cells by suppression of Wnt\/\u03b2-catenin pathway. Eur J Cancer. 2012;48:3310\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.013.","journal-title":"Eur J Cancer"},{"key":"7983_CR148","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/carcin\/bgv018","volume":"36","author":"MJ Young","year":"2015","unstructured":"Young MJ, Wu YH, Chiu WT, Weng TY, Huang YF, Chou CY. All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells. Carcinogenesis. 2015;36:498\u2013507. https:\/\/doi.org\/10.1093\/carcin\/bgv018.","journal-title":"Carcinogenesis"},{"key":"7983_CR149","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12906-016-1088-y","volume":"16","author":"Y Yan","year":"2016","unstructured":"Yan Y, Li Z, Xu X, Chen C, Wei W, Fan M, et al. All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy. BMC Complement Alter Med. 2016;16:113. https:\/\/doi.org\/10.1186\/s12906-016-1088-y.","journal-title":"BMC Complement Alter Med"},{"key":"7983_CR150","doi-asserted-by":"publisher","first-page":"34658","DOI":"10.18632\/oncotarget.26157","volume":"9","author":"SR Modarai","year":"2018","unstructured":"Modarai SR, Gupta A, Opdenaker LM, Kowash R, Masters G, Viswanathan V, et al. The anti-cancer effect of retinoic acid signaling in CRC occurs via decreased growth of ALDH+ colon cancer stem cells and increased differentiation of stem cells. Oncotarget. 2018;9:34658\u201369. https:\/\/doi.org\/10.18632\/oncotarget.26157.","journal-title":"Oncotarget"},{"key":"7983_CR151","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1038\/onc.2016.87","volume":"35","author":"PH Nguyen","year":"2016","unstructured":"Nguyen PH, Giraud J, Staedel C, Chambonnier L, Dubus P, Chevret E, et al. All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene. 2016;35:5619\u201328. https:\/\/doi.org\/10.1038\/onc.2016.87.","journal-title":"Oncogene"},{"key":"7983_CR152","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/a:1006032706362","volume":"16","author":"FL Meyskens Jr","year":"1998","unstructured":"Meyskens FL Jr, Jacobson J, Nguyen B, Weiss GR, Gandara DR, MacDonald JS. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest N. Drugs. 1998;16:171\u20133. https:\/\/doi.org\/10.1023\/a:1006032706362.","journal-title":"Invest N. Drugs"},{"key":"7983_CR153","first-page":"1255","volume":"24","author":"C Clerici","year":"2004","unstructured":"Clerici C, Castellani D, Russo G, Fiorucci S, Sabatino G, Giuliano V, et al. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma. Anticancer Res. 2004;24:1255\u201360.","journal-title":"Anticancer Res"},{"key":"7983_CR154","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1097\/CM9.0000000000001952","volume":"135","author":"J Sun","year":"2022","unstructured":"Sun J, Liu C, Shi J, Wang N, Jiang D, Mao F, et al. A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. Chin Med. 2022;135:2338\u201343. https:\/\/doi.org\/10.1097\/CM9.0000000000001952.","journal-title":"Chin Med"},{"key":"7983_CR155","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2147\/CMAR.S354170","volume":"14","author":"J Sun","year":"2022","unstructured":"Sun J, Liu C, Wang N, Jiang D, Zhang F, Shi J, et al. All-trans-retinoic acid plus oxaliplatin\/fluorouracil\/leucovorin for advanced hepatocellular carcinoma with pulmonary metastasis: a multicenter retrospective study. Cancer Manag Res. 2022;14:1663\u201370. https:\/\/doi.org\/10.2147\/CMAR.S354170.","journal-title":"Cancer Manag Res"},{"key":"7983_CR156","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41392-023-01604-3","volume":"8","author":"J Sun","year":"2023","unstructured":"Sun J, Mao F, Liu C, Zhang F, Jiang D, Guo W, et al. Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. Sig Transduct Target Ther. 2023;8:368. https:\/\/doi.org\/10.1038\/s41392-023-01604-3.","journal-title":"Sig Transduct Target Ther"},{"key":"7983_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.111739","volume":"386","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang F, Jiao K, Ju L, Liu Q, Li Y, et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-\u03baB pathway and CSC like properties. Exp Cell Res. 2020;386:111739. https:\/\/doi.org\/10.1016\/j.yexcr.2019.111739.","journal-title":"Exp Cell Res"},{"key":"7983_CR158","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/toxsci\/kfu218","volume":"143","author":"Y Li","year":"2015","unstructured":"Li Y, Jiang F, Liu Q, Shen J, Wang X, Li Z, et al. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Toxicol Sci. 2015;143:156\u201364. https:\/\/doi.org\/10.1093\/toxsci\/kfu218.","journal-title":"Toxicol Sci"},{"key":"7983_CR159","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1756-8722-7-28","volume":"7","author":"KZ Zhang","year":"2014","unstructured":"Zhang KZ, Zhang QB, Zhang QB, Sun HC, Ao JY, Chai ZT, et al. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014;7:28. https:\/\/doi.org\/10.1186\/1756-8722-7-28.","journal-title":"J Hematol Oncol"},{"key":"7983_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.335","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Hu B, Sun YF, Huang XW, Cheng JW, Huang A, et al. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF\/JAK1\/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021;11:e335. https:\/\/doi.org\/10.1002\/ctm2.335.","journal-title":"Clin Transl Med"},{"key":"7983_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1676-0","volume":"10","author":"HY Wang","year":"2019","unstructured":"Wang HY, Zhang B, Zhou JN, Wang DX, Xu YC, Zeng Q, et al. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF\/MCM7 complex. Cell Death Dis. 2019;10:453. https:\/\/doi.org\/10.1038\/s41419-019-1676-0.","journal-title":"Cell Death Dis"},{"key":"7983_CR162","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.7150\/thno.32462","volume":"9","author":"Y Huang","year":"2019","unstructured":"Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, et al. ZnAs@SiO2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1\/JAK2\/STAT3 signaling. Theranostics. 2019;9:4391\u2013408. https:\/\/doi.org\/10.7150\/thno.32462.","journal-title":"Theranostics"},{"key":"7983_CR163","doi-asserted-by":"publisher","first-page":"37300","DOI":"10.18632\/oncotarget.5836","volume":"6","author":"W Zhou","year":"2015","unstructured":"Zhou W, Cheng L, Shi Y, Ke SQ, Huang Z, Fang X, et al. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget. 2015;6:37300\u201315. https:\/\/doi.org\/10.18632\/oncotarget.5836.","journal-title":"Oncotarget"},{"key":"7983_CR164","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2147\/OTT.S49148","volume":"6","author":"JB Han","year":"2013","unstructured":"Han JB, Sang F, Chang JJ, Hua YQ, Shi WD, Tang LH, et al. Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli. Onco Targets Ther. 2013;6:1129\u201338. https:\/\/doi.org\/10.2147\/OTT.S49148.","journal-title":"Onco Targets Ther"},{"key":"7983_CR165","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-019-1077-3","volume":"38","author":"Y Lu","year":"2019","unstructured":"Lu Y, Liang Y, Zheng X, Deng X, Huang W, Zhang G. EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemo-\/radioresistance in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2019;38:82. https:\/\/doi.org\/10.1186\/s13046-019-1077-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"7983_CR166","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.21037\/tlcr-20-467","volume":"9","author":"KJ Chang","year":"2020","unstructured":"Chang KJ, Yin JZ, Huang H, Li B, Yang MH. Arsenic trioxide inhibits the growth of cancer stem cells derived from small cell lung cancer by downregulating stem cell-maintenance factors and inducing apoptosis via the Hedgehog signaling blockade. Transl Lung Cancer Res. 2020;9:1379\u201396. https:\/\/doi.org\/10.21037\/tlcr-20-467.","journal-title":"Transl Lung Cancer Res"},{"key":"7983_CR167","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10637-006-9004-9","volume":"25","author":"CC Lin","year":"2007","unstructured":"Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest N. Drugs. 2007;25:77\u201384. https:\/\/doi.org\/10.1007\/s10637-006-9004-9.","journal-title":"Invest N. Drugs"},{"key":"7983_CR168","first-page":"697","volume":"33","author":"FL Qu","year":"2011","unstructured":"Qu FL, Hao XZ, Qin SK, Liu JW, Sui GJ, Chen Q, et al. Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma. Zhonghua Zhong Liu Za Zhi. 2011;33:697\u2013701.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"7983_CR169","first-page":"971","volume":"51","author":"YL Meng","year":"2012","unstructured":"Meng YL, Hu HT, Li HL, Guo CY, Luo JP, Yao QJ, et al. The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases. Zhonghua Nei Ke Za Zhi. 2012;51:971\u20134.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"7983_CR170","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1002\/cncr.29456","volume":"121","author":"H Wang","year":"2015","unstructured":"Wang H, Liu Y, Wang X, Liu D, Sun Z, Wang C, et al. Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. Cancer. 2015;121:2917\u201325. https:\/\/doi.org\/10.1002\/cncr.29456.","journal-title":"Cancer"},{"key":"7983_CR171","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/jgh.13529","volume":"32","author":"HT Hu","year":"2017","unstructured":"Hu HT, Yao QJ, Meng YL, Li HL, Zhang H, Luo JP, et al. Arsenic trioxide intravenous infusion combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with pulmonary metastasis: Long-term outcome analysis. J Gastroenterol Hepatol. 2017;32:295\u2013300.","journal-title":"J Gastroenterol Hepatol"},{"key":"7983_CR172","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00432-014-1866-1","volume":"141","author":"B Liu","year":"2015","unstructured":"Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Oncol. 2015;141:1103\u20138. https:\/\/doi.org\/10.1007\/s00432-014-1866-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7983_CR173","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/jgh.13789","volume":"32","author":"XH Lv","year":"2017","unstructured":"Lv XH, Wang CH, Xie Y. Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: a meta-analysis. J Gastroenterol Hepatol. 2017;32:1540\u20137. https:\/\/doi.org\/10.1111\/jgh.13789.","journal-title":"J Gastroenterol Hepatol"},{"key":"7983_CR174","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00330-023-10097-1","volume":"34","author":"X Duan","year":"2024","unstructured":"Duan X, Li H, Chen P, Sun T, Kuang D, Lu H, et al. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study. Eur Radio. 2024;34:1258\u201367. https:\/\/doi.org\/10.1007\/s00330-023-10097-1.","journal-title":"Eur Radio"},{"key":"7983_CR175","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.26355\/eurrev_202002_20206","volume":"24","author":"XH Duan","year":"2020","unstructured":"Duan XH, Ju SG, Han XW, Ren JZ, Li FY, Chen PF, et al. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide\/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur Rev Med Pharm Sci. 2020;24:1468\u201380. https:\/\/doi.org\/10.26355\/eurrev_202002_20206.","journal-title":"Eur Rev Med Pharm Sci"},{"key":"7983_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35662","volume":"131","author":"WY Jen","year":"2025","unstructured":"Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, Jabbour E, et al. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2025;131:e35662. https:\/\/doi.org\/10.1002\/cncr.35662.","journal-title":"Cancer"},{"key":"7983_CR177","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3760\/cma.j.cn112140-20240224-00120","volume":"62","author":"S Yang","year":"2024","unstructured":"Yang S, Chen KL, He YY, Peng XM, Xiong H, Jia WW, et al. Short-term results of a multicenter study based on a modified N7 induction regimen combined with arsenic trioxide in the treatment of children with high-risk neuroblastoma. Zhonghua Er Ke Za Zhi. 2024;62:949\u201355. https:\/\/doi.org\/10.3760\/cma.j.cn112140-20240224-00120.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"7983_CR178","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0526-x","volume":"32","author":"H Zhao","year":"2015","unstructured":"Zhao H, Sun G, Kong D, Zhang Y, Shi W, Zhao M, et al. A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma. Med Oncol. 2015;32:79. https:\/\/doi.org\/10.1007\/s12032-015-0526-x.","journal-title":"Med Oncol"},{"key":"7983_CR179","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3109\/07357907.2012.756109","volume":"31","author":"LA Held","year":"2013","unstructured":"Held LA, Rizzieri D, Long GD, Gockerman JP, Diehl LF, de Castro CM, et al. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed\/refractory multiple myeloma. Cancer Invest. 2013;31:172\u20136. https:\/\/doi.org\/10.3109\/07357907.2012.756109.","journal-title":"Cancer Invest"},{"key":"7983_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0384-5","volume":"9","author":"B Rani","year":"2018","unstructured":"Rani B, Malfettone A, Dituri F, Soukupova J, Lupo L, Mancarella S, et al. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. Cell Death Dis. 2018;9:373. https:\/\/doi.org\/10.1038\/s41419-018-0384-5.","journal-title":"Cell Death Dis"},{"key":"7983_CR181","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1158\/1078-0432.CCR-14-1936","volume":"21","author":"T Kawai","year":"2015","unstructured":"Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, et al. Keratin 19, a cancer stem cell marker in human hepatocellular carcinoma. Clin Cancer Res. 2015;21:3081\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1936.","journal-title":"Clin Cancer Res"},{"key":"7983_CR182","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-16-1743","volume":"23","author":"HC Tran","year":"2017","unstructured":"Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, et al. TGF\u03b2R1 blockade with galunisertib (LY2157299) enhances anti-neuroblastoma activity of the anti-GD2 antibody dinutuximab (ch14.18) with natural killer cells. Clin Cancer Res. 2017;23:804\u201313. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1743.","journal-title":"Clin Cancer Res"},{"key":"7983_CR183","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1158\/0008-5472.CAN-15-2946","volume":"76","author":"SK Yeo","year":"2016","unstructured":"Yeo SK, Wen J, Chen S, Guan JL. Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR\/Stat3 and Tgf\u03b2\/Smad signaling. Cancer Res. 2016;76:3397\u2013410. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2946.","journal-title":"Cancer Res"},{"key":"7983_CR184","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.stem.2011.10.001","volume":"9","author":"E Lonardo","year":"2011","unstructured":"Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal\/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433\u201346. https:\/\/doi.org\/10.1016\/j.stem.2011.10.001.","journal-title":"Cell Stem Cell"},{"key":"7983_CR185","doi-asserted-by":"publisher","first-page":"e00056","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"RK Kelley","year":"2019","unstructured":"Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, et al. A phase 2 study of galunisertib (TGF-\u03b21 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol. 2019;10:e00056. https:\/\/doi.org\/10.14309\/ctg.0000000000000056.","journal-title":"Clin Transl Gastroenterol"},{"key":"7983_CR186","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1002\/cam4.3880","volume":"10","author":"JJ Harding","year":"2021","unstructured":"Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, et al. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med. 2021;10:3059\u201367. https:\/\/doi.org\/10.1002\/cam4.3880.","journal-title":"Cancer Med"},{"key":"7983_CR187","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10637-018-0636-3","volume":"37","author":"M Ikeda","year":"2019","unstructured":"Ikeda M, Morimoto M, Tajimi M, Inoue K, Benhadji KA, Lahn MMF, et al. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Invest N Drugs. 2019;37:118\u201326. https:\/\/doi.org\/10.1007\/s10637-018-0636-3.","journal-title":"Invest N Drugs"},{"key":"7983_CR188","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/liv.14113","volume":"39","author":"S Faivre","year":"2019","unstructured":"Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019;39:1468\u201377. https:\/\/doi.org\/10.1111\/liv.14113.","journal-title":"Liver Int"},{"key":"7983_CR189","doi-asserted-by":"publisher","first-page":"e0222259","DOI":"10.1371\/journal.pone.0222259","volume":"15","author":"G Giannelli","year":"2020","unstructured":"Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, et al. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-\u03b2RI inhibitor galunisertib. PLoS One. 2020;15:e0222259. https:\/\/doi.org\/10.1371\/journal.pone.0222259.","journal-title":"PLoS One"},{"key":"7983_CR190","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11153-1","volume":"23","author":"E Nadal","year":"2023","unstructured":"Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, et al. A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 2023;23:708. https:\/\/doi.org\/10.1186\/s12885-023-11153-1.","journal-title":"BMC Cancer"},{"key":"7983_CR191","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00280-019-03807-4","volume":"83","author":"D Melisi","year":"2019","unstructured":"Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, et al. TGF\u03b2 receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharm. 2019;83:975\u201391. https:\/\/doi.org\/10.1007\/s00280-019-03807-4.","journal-title":"Cancer Chemother Pharm"},{"key":"7983_CR192","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","volume":"23","author":"T Yamazaki","year":"2022","unstructured":"Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, et al. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol. 2022;23:1189\u20131200. https:\/\/doi.org\/10.1016\/S1470-2045(22)00446-6.","journal-title":"Lancet Oncol"},{"key":"7983_CR193","first-page":"17","volume":"34","author":"B Petrushev","year":"2012","unstructured":"Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, et al. Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol. 2012;34:17\u201324.","journal-title":"Exp Oncol"},{"key":"7983_CR194","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.neo.2019.03.007","volume":"21","author":"O Maehara","year":"2019","unstructured":"Maehara O, Ohnishi S, Asano A, Suda G, Natsuizaka M, Nakagawa K, et al. Metformin regulates the expression of CD133 through the AMPK-CEBP\u03b2 pathway in hepatocellular carcinoma cell lines. Neoplasia. 2019;21:545\u201356. https:\/\/doi.org\/10.1016\/j.neo.2019.03.007.","journal-title":"Neoplasia"},{"key":"7983_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01177-6","volume":"7","author":"R Zhang","year":"2017","unstructured":"Zhang R, Yao RR, Li JH, Dong G, Ma M, Zheng QD, et al. Activated hepatic stellate cells secrete periostin to induce stem cell-like phenotype of residual hepatocellular carcinoma cells after heat treatment. Sci Rep. 2017;7:2164. https:\/\/doi.org\/10.1038\/s41598-017-01177-6.","journal-title":"Sci Rep"},{"key":"7983_CR196","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.3390\/ijms22073315","volume":"22","author":"ACK Lee","year":"2021","unstructured":"Lee ACK, Lau PM, Kwan YW, Kong SK. Mitochondrial fuel dependence on glutamine drives chemo-resistance in the cancer stem cells of hepatocellular carcinoma. Int J Mol Sci. 2021;22:3315. https:\/\/doi.org\/10.3390\/ijms22073315.","journal-title":"Int J Mol Sci"},{"key":"7983_CR197","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.7150\/jca.10047","volume":"7","author":"HW Xin","year":"2016","unstructured":"Xin HW, Ambe CM, Miller TC, Chen JQ, Wiegand GW, Anderson AJ, et al. Liver label retaining cancer cells are relatively resistant to the reported anti-cancer stem cell drug metformin. J Cancer. 2016;7:1142\u201351. https:\/\/doi.org\/10.7150\/jca.10047.","journal-title":"J Cancer"},{"key":"7983_CR198","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jhep.2020.12.031","volume":"74","author":"C Raggi","year":"2021","unstructured":"Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, et al. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol. 2021;74:1373\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2020.12.031.","journal-title":"J Hepatol"},{"key":"7983_CR199","doi-asserted-by":"publisher","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","volume":"69","author":"HA Hirsch","year":"2009","unstructured":"Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507\u201311. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2994.","journal-title":"Cancer Res"},{"key":"7983_CR200","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1158\/0008-5472.CAN-10-3471","volume":"71","author":"D Iliopoulos","year":"2011","unstructured":"Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71:3196\u2013201. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3471.","journal-title":"Cancer Res"},{"key":"7983_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04842-5","volume":"13","author":"JS Yan","year":"2022","unstructured":"Yan JS, Yang MY, Zhang XH, Luo CH, Du CK, Jiang Y, et al. Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells. Cell Death Dis. 2022;13:384. https:\/\/doi.org\/10.1038\/s41419-022-04842-5.","journal-title":"Cell Death Dis"},{"key":"7983_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18762-4","volume":"8","author":"JH Kim","year":"2018","unstructured":"Kim JH, Lee KJ, Seo Y, Kwon JH, Yoon JP, Kang JY, et al. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Sci Rep. 2018;8:409. https:\/\/doi.org\/10.1038\/s41598-017-18762-4.","journal-title":"Sci Rep"},{"key":"7983_CR203","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2017.07.020","volume":"84","author":"S Courtois","year":"2017","unstructured":"Courtois S, Dur\u00e1n RV, Giraud J, Sifr\u00e9 E, Izotte J, M\u00e9graud F, et al. Metformin targets gastric cancer stem cells. Eur J Cancer. 2017;84:193\u2013201. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.020.","journal-title":"Eur J Cancer"},{"key":"7983_CR204","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9290728","volume":"2019","author":"B Zhao","year":"2019","unstructured":"Zhao B, Luo J, Wang Y, Zhou L, Che J, Wang F, et al. Metformin suppresses self-renewal ability and tumorigenicity of osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy. Oxid Med Cell Longev. 2019;2019:9290728. https:\/\/doi.org\/10.1155\/2019\/9290728.","journal-title":"Oxid Med Cell Longev"},{"key":"7983_CR205","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fonc.2019.00135","volume":"9","author":"F Barbieri","year":"2019","unstructured":"Barbieri F, Verduci I, Carlini V, Zona G, Pagano A, Mazzanti M, et al. Repurposed biguanide drugs in glioblastoma exert antiproliferative effects via the inhibition of intracellular chloride channel 1 activity. Front Oncol. 2019;9:135. https:\/\/doi.org\/10.3389\/fonc.2019.00135.","journal-title":"Front Oncol"},{"key":"7983_CR206","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.biocel.2018.12.016","volume":"107","author":"A Bishnu","year":"2019","unstructured":"Bishnu A, Sakpal A, Ghosh N, Choudhury P, Chaudhury K, Ray P. Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells. Int J Biochem Cell Biol. 2019;107:116\u201327. https:\/\/doi.org\/10.1016\/j.biocel.2018.12.016.","journal-title":"Int J Biochem Cell Biol"},{"key":"7983_CR207","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/15384101.2015.1127471","volume":"15","author":"X Ning","year":"2016","unstructured":"Ning X, Du Y, Ben Q, Huang L, He X, Gong Y, et al. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. Cell Cycle. 2016;15:403\u201312. https:\/\/doi.org\/10.1080\/15384101.2015.1127471.","journal-title":"Cell Cycle"},{"key":"7983_CR208","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.18632\/oncotarget.26817","volume":"10","author":"Z Xiao","year":"2019","unstructured":"Xiao Z, Sperl B, G\u00e4rtner S, Nedelko T, Stacher-Priehse E, Ullrich A, et al. Lung cancer stem cells and their aggressive progeny, controlled by EGFR\/MIG6 inverse expression, dictate a novel NSCLC treatment approach. Oncotarget. 2019;10:2546\u201360. https:\/\/doi.org\/10.18632\/oncotarget.26817.","journal-title":"Oncotarget"},{"key":"7983_CR209","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/cancers11050653","volume":"11","author":"SJ Kitson","year":"2019","unstructured":"Kitson SJ, Rosser M, Fischer DP, Marshall KM, Clarke RB, Crosbie EJ. Targeting endometrial cancer stem cell activity with metformin is inhibited by patient-derived adipocyte-secreted factors. Cancers. 2019;11:653. https:\/\/doi.org\/10.3390\/cancers11050653.","journal-title":"Cancers"},{"key":"7983_CR210","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3892\/ijo.2014.2450","volume":"45","author":"S Honjo","year":"2014","unstructured":"Honjo S, Ajani JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, et al. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. Int J Oncol. 2014;45:567\u201374. https:\/\/doi.org\/10.3892\/ijo.2014.2450.","journal-title":"Int J Oncol"},{"key":"7983_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2020.104710","volume":"113","author":"S Patil","year":"2020","unstructured":"Patil S. Metformin treatment decreases the expression of cancer stem cell marker CD44 and stemness related gene expression in primary oral cancer cells. Arch Oral Biol. 2020;113:104710. https:\/\/doi.org\/10.1016\/j.archoralbio.2020.104710.","journal-title":"Arch Oral Biol"},{"key":"7983_CR212","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/hep.32244","volume":"75","author":"JR Kramer","year":"2022","unstructured":"Kramer JR, Natarajan Y, Dai J, Yu X, Li L, El-Serag HB, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022;75:1420\u20138. https:\/\/doi.org\/10.1002\/hep.32244.","journal-title":"Hepatology"},{"key":"7983_CR213","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hep4.1640","volume":"5","author":"ZN Memel","year":"2020","unstructured":"Memel ZN, Arvind A, Moninuola O, Philpotts L, Chung RT, Corey KE, et al. Aspirin use is associated with a reduced incidence of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Commun. 2020;5:133\u201343. https:\/\/doi.org\/10.1002\/hep4.1640.","journal-title":"Hepatol Commun"},{"key":"7983_CR214","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/apt.17371","volume":"57","author":"RW Zeng","year":"2023","unstructured":"Zeng RW, Yong JN, Tan DJH, Fu CE, Lim WH, Xiao J, et al. Meta-analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharm Ther. 2023;57:600\u20139. https:\/\/doi.org\/10.1111\/apt.17371.","journal-title":"Aliment Pharm Ther"},{"key":"7983_CR215","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.aohep.2019.11.008","volume":"19","author":"J Zhou","year":"2020","unstructured":"Zhou J, Ke Y, Lei X, Wu T, Li Y, Bao T, et al. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. Ann Hepatol. 2020;19:320\u20138. https:\/\/doi.org\/10.1016\/j.aohep.2019.11.008.","journal-title":"Ann Hepatol"},{"key":"7983_CR216","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1060768","volume":"13","author":"B Yuan","year":"2022","unstructured":"Yuan B, Ma J, Wang J, Hao J. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy. Front Endocrinol. 2022;13:1060768. https:\/\/doi.org\/10.3389\/fendo.2022.1060768.","journal-title":"Front Endocrinol"},{"key":"7983_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101781","volume":"46","author":"Q Li","year":"2022","unstructured":"Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol. 2022;46:101781. https:\/\/doi.org\/10.1016\/j.clinre.2021.101781.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"7983_CR218","doi-asserted-by":"publisher","first-page":"e0247231","DOI":"10.1371\/journal.pone.0247231","volume":"16","author":"WR Cho","year":"2021","unstructured":"Cho WR, Wang CC, Tsai MY, Chou CK, Liu YW, Wu YJ, et al. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS One. 2021;16:e0247231. https:\/\/doi.org\/10.1371\/journal.pone.0247231.","journal-title":"PLoS One"},{"key":"7983_CR219","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2147\/JHC.S304439","volume":"8","author":"YY Cho","year":"2021","unstructured":"Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, et al. Clinical characteristics of long-term survivors after sorafenib treatment for unresectable hepatocellular carcinoma: a Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma. 2021;8:613\u201323. https:\/\/doi.org\/10.2147\/JHC.S304439.","journal-title":"J Hepatocell Carcinoma"},{"key":"7983_CR220","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/MCG.0000000000001182","volume":"54","author":"SO Antwi","year":"2020","unstructured":"Antwi SO, Li Z, Mody K, Roberts LR, Patel T. Independent and joint use of statins and metformin by elderly patients with diabetes and overall survival following HCC diagnosis. J Clin Gastroenterol. 2020;54:468\u201376. https:\/\/doi.org\/10.1097\/MCG.0000000000001182.","journal-title":"J Clin Gastroenterol"},{"key":"7983_CR221","doi-asserted-by":"publisher","first-page":"e0244293","DOI":"10.1371\/journal.pone.0244293","volume":"15","author":"MH Hsieh","year":"2020","unstructured":"Hsieh MH, Kao TY, Hsieh TH, Kao CC, Peng CY, Lai HC, et al. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. PLoS One. 2020;15:e0244293. https:\/\/doi.org\/10.1371\/journal.pone.0244293.","journal-title":"PLoS One"},{"key":"7983_CR222","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clinthera.2021.12.011","volume":"44","author":"TJ Hydes","year":"2022","unstructured":"Hydes TJ, Cuthbertson DJ, Graef S, Berhane S, Teng M, Skowronska A, et al. The impact of diabetes and glucose-lowering therapies on hepatocellular carcinoma incidence and overall survival. Clin Ther. 2022;44:257\u201368. https:\/\/doi.org\/10.1016\/j.clinthera.2021.12.011.","journal-title":"Clin Ther"},{"key":"7983_CR223","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.55730\/1300-0144.5498","volume":"52","author":"NA Azit","year":"2022","unstructured":"Azit NA, Sahran S, Meng LV, Subramaniam MK, Mokhtar S, Nawi AM. The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study. Turk J Med Sci. 2022;52:1580\u201390. https:\/\/doi.org\/10.55730\/1300-0144.5498.","journal-title":"Turk J Med Sci"},{"key":"7983_CR224","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12029-020-00389-w","volume":"52","author":"S El Shorbagy","year":"2021","unstructured":"El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, et al. Prognostic significance of VEGF and HIF-1 \u03b1 in hepatocellular carcinoma patients receiving sorafenib versus metformin sorafenib combination. J Gastrointest Cancer. 2021;52:269\u201379. https:\/\/doi.org\/10.1007\/s12029-020-00389-w.","journal-title":"J Gastrointest Cancer"},{"key":"7983_CR225","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/oncolo\/oyab008","volume":"27","author":"V Ostwal","year":"2022","unstructured":"Ostwal V, Ramaswamy A, Gota V, Bhargava PG, Srinivas S, Shriyan B, et al. Phase I study evaluating dose de-escalation of sorafenib with metformin and atorvastatin in hepatocellular carcinoma (SMASH). Oncologist. 2022;27:165\u2013e222. https:\/\/doi.org\/10.1093\/oncolo\/oyab008.","journal-title":"Oncologist"},{"key":"7983_CR226","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133247","volume":"5","author":"JR Brown","year":"2020","unstructured":"Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, et al. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020;5:e133247. https:\/\/doi.org\/10.1172\/jci.insight.133247.","journal-title":"JCI Insight"},{"key":"7983_CR227","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.31557\/APJCP.2024.25.7.2351","volume":"25","author":"A Hegazy","year":"2024","unstructured":"Hegazy A, Ali MS, Mubarak NA, Alagizy HAM, Sohaib A. Metformin in combination with standard therapy in patients with diffuse large B-cell lymphoma: a randomized phase II clinical trial. Asian Pac J Cancer Prev. 2024;25:2351\u20139. https:\/\/doi.org\/10.31557\/APJCP.2024.25.7.2351.","journal-title":"Asian Pac J Cancer Prev"},{"key":"7983_CR228","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10585-016-9782-1","volume":"33","author":"SM El-Haggar","year":"2016","unstructured":"El-Haggar SM, El-Shitany NA, Mostafa MF, El-Bassiouny NA. Metformin may protect nondiabetic breast cancer women from metastasis. Clin Exp Metastasis. 2016;33:339\u201357. https:\/\/doi.org\/10.1007\/s10585-016-9782-1.","journal-title":"Clin Exp Metastasis"},{"key":"7983_CR229","doi-asserted-by":"publisher","first-page":"831.e1","DOI":"10.1016\/j.urolonc.2021.05.020","volume":"39","author":"R Alghandour","year":"2021","unstructured":"Alghandour R, Ebrahim MA, Elshal AM, Ghobrial F, Elzaafarany M, ELbaiomy MA. Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED). Urol Oncol. 2021;39:831.e1\u2013831.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.020.","journal-title":"Urol Oncol"},{"key":"7983_CR230","doi-asserted-by":"publisher","first-page":"e192553","DOI":"10.1001\/jamaoncol.2019.2553","volume":"5","author":"O Arrieta","year":"2019","unstructured":"Arrieta O, Barr\u00f3n F, Padilla MS, Avil\u00e9s-Salas A, Ram\u00edrez-Tirado LA, Arguelles Jim\u00e9nez MJ, et al. Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:e192553. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2553.","journal-title":"JAMA Oncol"},{"key":"7983_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01315-9","volume":"20","author":"XD Yang","year":"2021","unstructured":"Yang XD, Kong FE, Qi L, Lin JX, Yan Q, Loong JHC, et al. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer. 2021;20:20. https:\/\/doi.org\/10.1186\/s12943-021-01315-9.","journal-title":"Mol Cancer"},{"key":"7983_CR232","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12282-012-0356-z","volume":"21","author":"T Shimo","year":"2014","unstructured":"Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, et al. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. Breast Cancer. 2014;21:75\u201385. https:\/\/doi.org\/10.1007\/s12282-012-0356-z.","journal-title":"Breast Cancer"},{"key":"7983_CR233","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/cdd.2013.136","volume":"21","author":"M Venere","year":"2014","unstructured":"Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 2014;21:258\u201369. https:\/\/doi.org\/10.1038\/cdd.2013.136.","journal-title":"Cell Death Differ"},{"key":"7983_CR234","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/stem.2929","volume":"37","author":"A Jarrar","year":"2019","unstructured":"Jarrar A, Lotti F, DeVecchio J, Ferrandon S, Gantt G, Mace A, et al. Poly(ADP-Ribose) polymerase inhibition sensitizes colorectal cancer-initiating cells to chemotherapy. Stem Cells. 2019;37:42\u201353. https:\/\/doi.org\/10.1002\/stem.2929.","journal-title":"Stem Cells"},{"key":"7983_CR235","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1158\/1541-7786.MCR-18-0594","volume":"17","author":"C Bellio","year":"2019","unstructured":"Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, et al. PARP inhibition induces enrichment of DNA repair-proficient CD133 and CD117 positive ovarian cancer stem cells. Mol Cancer Res. 2019;17:431\u201345. https:\/\/doi.org\/10.1158\/1541-7786.MCR-18-0594.","journal-title":"Mol Cancer Res"},{"key":"7983_CR236","doi-asserted-by":"publisher","first-page":"e22312","DOI":"10.1097\/MD.0000000000022312","volume":"99","author":"F Zhao","year":"2020","unstructured":"Zhao F, Zhou Y, Seesaha PK, Zhang Y, Liu S, Gan X, et al. Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report. Medicine. 2020;99:e22312. https:\/\/doi.org\/10.1097\/MD.0000000000022312.","journal-title":"Medicine"},{"key":"7983_CR237","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.2147\/OTT.S317514","volume":"14","author":"YL Su","year":"2021","unstructured":"Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT. Remarkable response to olaparib in a patient with combined hepatocellular-cholangiocarcinoma harboring a biallelic BRCA2 mutation. Onco Targets Ther. 2021;14:3895\u2013901. https:\/\/doi.org\/10.2147\/OTT.S317514.","journal-title":"Onco Targets Ther"},{"key":"7983_CR238","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1010158","volume":"12","author":"C Li","year":"2022","unstructured":"Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z. Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer. Front Oncol. 2022;12:1010158. https:\/\/doi.org\/10.3389\/fonc.2022.1010158.","journal-title":"Front Oncol"},{"key":"7983_CR239","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102041","volume":"8","author":"S Joris","year":"2023","unstructured":"Joris S, Denys H, Collignon J, Rasschaert M, T\u2019Kint de Roodenbeke D, Duhoux FP, et al. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. ESMO Open. 2023;8:102041. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102041.","journal-title":"ESMO Open"},{"key":"7983_CR240","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hep.28367","volume":"63","author":"KH Jung","year":"2016","unstructured":"Jung KH, Zhang J, Zhou C, Shen H, Gagea M, Rodriguez-Aguayo C, et al. Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis. Hepatology. 2016;63:864\u201379. https:\/\/doi.org\/10.1002\/hep.28367.","journal-title":"Hepatology"},{"key":"7983_CR241","doi-asserted-by":"publisher","first-page":"e25264","DOI":"10.1371\/journal.pone.0025264","volume":"6","author":"C Huynh","year":"2011","unstructured":"Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One. 2011;6:e25264. https:\/\/doi.org\/10.1371\/journal.pone.0025264.","journal-title":"PLoS One"},{"key":"7983_CR242","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/15384047.2016.1210737","volume":"17","author":"ME Issa","year":"2016","unstructured":"Issa ME, Berndt S, Carpentier G, Pezzuto JM, Cuendet M. Bruceantin inhibits multiple myeloma cancer stem cell proliferation. Cancer Biol Ther. 2016;17:966\u201375. https:\/\/doi.org\/10.1080\/15384047.2016.1210737.","journal-title":"Cancer Biol Ther"},{"key":"7983_CR243","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-012-2075-8","volume":"134","author":"BG Debeb","year":"2012","unstructured":"Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012;134:495\u2013510. https:\/\/doi.org\/10.1007\/s10549-012-2075-8.","journal-title":"Breast Cancer Res Treat"},{"key":"7983_CR244","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s10637-013-0001-5","volume":"31","author":"I Diaz-Padilla","year":"2013","unstructured":"Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest N. Drugs. 2013;31:1182\u201391. https:\/\/doi.org\/10.1007\/s10637-013-0001-5.","journal-title":"Invest N. Drugs"},{"key":"7983_CR245","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201008","volume":"33","author":"FP de Oliveira","year":"2025","unstructured":"de Oliveira FP, Nogueira ML, Galv\u00e3o AFC, Dias RB, Bezerra DP. Translational drugs targeting cancer stem cells in triple-negative breast cancer. Mol Ther Oncol. 2025;33:201008. https:\/\/doi.org\/10.1016\/j.omton.2025.201008.","journal-title":"Mol Ther Oncol"},{"key":"7983_CR246","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","volume":"22","author":"A Britschgi","year":"2012","unstructured":"Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, M\u00fcller U, et al. JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012;22:796\u2013811. https:\/\/doi.org\/10.1016\/j.ccr.2012.10.023.","journal-title":"Cancer Cell"},{"key":"7983_CR247","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-09-0014","volume":"69","author":"Q Du","year":"2009","unstructured":"Du Q, Zhang X, Cardinal J, Cao Z, Guo Z, Shao L, et al. Wnt\/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res. 2009;69:3764\u201371. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-0014.","journal-title":"Cancer Res"},{"key":"7983_CR248","doi-asserted-by":"publisher","first-page":"8572","DOI":"10.1158\/0008-5472.CAN-09-1500","volume":"69","author":"FK Noubissi","year":"2009","unstructured":"Noubissi FK, Goswami S, Sanek NA, Kawakami K, Minamoto T, Moser A, et al. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 2009;69:8572\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1500.","journal-title":"Cancer Res"},{"key":"7983_CR249","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3892\/ijo.2014.2310","volume":"44","author":"RY Liu","year":"2014","unstructured":"Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu Z, et al. JAK\/STAT3 signaling is required for TGF-\u03b2-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014;44:1643\u201351. https:\/\/doi.org\/10.3892\/ijo.2014.2310.","journal-title":"Int J Oncol"},{"key":"7983_CR250","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-17-0421","volume":"17","author":"XX Quan","year":"2018","unstructured":"Quan XX, Hawk NV, Chen W, Coupar J, Lee SK, Petersen DW, et al. Targeting Notch1 and IKK\u03b1 enhanced NF-\u03baB activation in CD133+ skin cancer stem cells. Mol Cancer Ther. 2018;17:2034\u201348. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0421.","journal-title":"Mol Cancer Ther"},{"key":"7983_CR251","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1053\/j.gastro.2007.04.025","volume":"132","author":"S Ma","year":"2007","unstructured":"Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem\/progenitor cells. Gastroenterology. 2007;132:2542\u201356. https:\/\/doi.org\/10.1053\/j.gastro.2007.04.025.","journal-title":"Gastroenterology"},{"key":"7983_CR252","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.stem.2011.06.005","volume":"9","author":"TK Lee","year":"2011","unstructured":"Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9:50\u201363. https:\/\/doi.org\/10.1016\/j.stem.2011.06.005.","journal-title":"Cell Stem Cell"},{"key":"7983_CR253","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hep.27070","volume":"60","author":"TK Lee","year":"2014","unstructured":"Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, et al. Blockade of CD47-mediated cathepsin S\/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:179\u201391. https:\/\/doi.org\/10.1002\/hep.27070.","journal-title":"Hepatology"},{"key":"7983_CR254","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1089\/scd.2015.0202","volume":"24","author":"C Zeng","year":"2015","unstructured":"Zeng C, Zhang Y, Park SC, Eun JR, Nguyen NT, Tschudy-Seney B, et al. CD34(+) Liver Cancer Stem Cells Were Formed by Fusion of Hepatobiliary Stem\/Progenitor Cells with Hematopoietic Precursor-Derived Myeloid Intermediates. Stem Cells Dev. 2015;24:2467\u201378. https:\/\/doi.org\/10.1089\/scd.2015.0202.","journal-title":"Stem Cells Dev"},{"key":"7983_CR255","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3892\/ol.2019.10673","volume":"18","author":"W Fan","year":"2019","unstructured":"Fan W, Yang X, Huang F, Tong X, Zhu L, Wang S. Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer. Oncol Lett. 2019;18:3218\u201326. https:\/\/doi.org\/10.3892\/ol.2019.10673.","journal-title":"Oncol Lett"},{"key":"7983_CR256","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13045-020-0845-z","volume":"13","author":"XL Ma","year":"2020","unstructured":"Ma XL, Hu B, Tang WG, Xie SH, Ren N, Guo L, et al. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol. 2020;13:11. https:\/\/doi.org\/10.1186\/s13045-020-0845-z.","journal-title":"J Hematol Oncol"},{"key":"7983_CR257","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jhep.2012.04.024","volume":"57","author":"W Yang","year":"2012","unstructured":"Yang W, Wang C, Lin Y, Liu Q, Yu LX, Tang L, et al. OV6\u207a tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol. 2012;57:613\u201320. https:\/\/doi.org\/10.1016\/j.jhep.2012.04.024.","journal-title":"J Hepatol"},{"key":"7983_CR258","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1053\/j.gastro.2013.01.046","volume":"144","author":"S Liu","year":"2013","unstructured":"Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 2013;144:1031\u20131041.e10. https:\/\/doi.org\/10.1053\/j.gastro.2013.01.046.","journal-title":"Gastroenterology"},{"key":"7983_CR259","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/onc.2015.129","volume":"34","author":"ZJ Lei","year":"2015","unstructured":"Lei ZJ, Wang J, Xiao HL, Guo Y, Wang T, Li Q, et al. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of \u03b2-catenin signaling. Oncogene. 2015;34:3188\u201398. https:\/\/doi.org\/10.1038\/onc.2015.129.","journal-title":"Oncogene"},{"key":"7983_CR260","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ccr.2013.02.025","volume":"23","author":"W Zhao","year":"2013","unstructured":"Zhao W, Wang L, Han H, Jin K, Lin N, Guo T, et al. 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel \u03b12\u03b41 subunit. Cancer Cell. 2013;23:541\u201356. https:\/\/doi.org\/10.1016\/j.ccr.2013.02.025.","journal-title":"Cancer Cell"},{"key":"7983_CR261","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1535-7163.MCT-11-0531","volume":"11","author":"X Xu","year":"2012","unstructured":"Xu X, Liu RF, Zhang X, Huang LY, Chen F, Fei QL, et al. DLK1 as a potential target against cancer stem\/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther. 2012;11:629\u201338. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0531.","journal-title":"Mol Cancer Ther"},{"key":"7983_CR262","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.MCR-08-0035","volume":"6","author":"S Ma","year":"2008","unstructured":"Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6:1146\u201353. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0035.","journal-title":"Mol Cancer Res"},{"key":"7983_CR263","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ijc.30553","volume":"140","author":"M Zhu","year":"2017","unstructured":"Zhu M, Li W, Lu Y, Dong X, Lin B, Chen Y, et al. HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K\/AKT signal pathway. Int J Cancer. 2017;140:1346\u201355. https:\/\/doi.org\/10.1002\/ijc.30553.","journal-title":"Int J Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07983-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07983-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07983-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T02:37:05Z","timestamp":1757471825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07983-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":263,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7983"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07983-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"666"}}